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Abstract
Obesity is a multifactorial disease resulting in excessive accumulation of adipose tissue. Over the last decade, growing
evidence has identiﬁed the gut microbiota as a potential factor in the pathophysiology of both obesity and the related
metabolic disorders. The gut microbiota is known to protect gastrointestinal mucosa permeability and to regulate the
fermentation and absorption of dietary polysaccharides, perhaps explaining its importance in the regulation of fat
accumulation and the resultant obesity. The proposed mechanisms by which the gut microbiota could contribute to the
pathogenesis of obesity and the related metabolic diseases include: (a) a high abundance of bacteria that ferment
carbohydrates, leading to increased rates of short-chain fatty acid (SCFA) biosynthesis, providing an extra source of energy
for the host, that is eventually stored as lipids or glucose; (b) increased intestinal permeability to bacterial
lipopolysaccharides (LPS), resulting in elevated systemic LPS levels that aggravate low-grade inﬂammation and insulin
resistance; (c) increased activity of the gut endocannabinoid system. Fecal transplantation studies in germ-free mice
have provided crucial insights into the potential causative role of the gut microbiota in the development of obesity and
obesity-related disorders. Diet +/− bariatric surgery have been reported to modulate the gut microbiota, leading to lean
host phenotype body composition. This review aims to report clinical evidence for a link of the gut microbiota with
human obesity and obesity-related diseases, to provide molecular insights into these associations, and to address the effect of
diet and bariatric surgery on the gut microbiota, including colonic microbiota, as a potential mechanism for promoting
weight loss.
Introduction
The gut microbiota has recently been reported to have a role
in the pathogenesis of cardiometabolic diseases. The com-
ponent organisms contain more than 100 genes compared
with the human genome [1]. One role of the gut bacteria is
to protect and support the intestinal mucosa in close sym-
biotic relationships with the host’s body. This close rela-
tionship allows the gut microbiota bacteria to contribute to
physiological homeostasis, and abnormalities of the gut
microbiota are reported to contribute to the development of
several diseases [2].
In metabolic disease, including obesity, the gut microbiota
is altered so as to increase energy harvesting from the diet
[2]. Indeed, the gut microbiota has an important role in the
regulation of fat storage [3], increasing energy harvesting,
and in modulating the formation of substrates for storable fat
synthesis [4]; in addition, the gut microbiota produces
compounds absorbed into the systemic circulation that are
likely to contribute to the development of obesity-related
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complications, since they increase both tissue inﬂammatory
damage and insulin resistance [5]. Changes of the gut
microbiota in early life have also been reported to encourage
the onset of obesity due to adverse effects on mechanisms
regulating satiety/appetite [6, 7]. Overall, obesity is asso-
ciated with the gut microbiota that have reduced the diversity
of their composition, which, in turn, reduces metabolic
energy consumption in comparison with that of the micro-
biota of lean people [8]; since microbiota facilitating efﬁcient
fermentation [digestion] of indigestible carbohydrates into
short-chain fatty acids provide excess energy substrate to the
host, that then contributes to the development of obesity,
while low-efﬁciency gut bacterial breakdown of complex
carbohydrates could contribute to avoidance of the devel-
opment of obesity.
Based on this information, it has been hypothesized that
modulation of the gut microbiota might provide a novel
treatment target in obesity. Several environmental factors,
including diet, as well as gut microbiota composition,
inﬂuence host metabolism [9]; for example, chronic intake
of the Mediterranean diet (MD) over 2 years can normalize
gut microbiota actions, paralleling reductions in insulin
resistance, in obese patients with coronary heart disease
[10, 11]. Adherence to the MD has been associated with
the healthy gut microbiota, as assessed by quantitative
PCR and plate-count techniques in adults [12]. Bariatric
surgery is increasingly used to treat obesity, and in morbid
obesity, it may be the most effective treatment option
for achieving weight loss [13] through various surgical
techniques, sometimes reducing food entry into the
stomach using a gastric band, sometimes removing a
portion of the stomach, and sometimes by removing
sections of the stomach and re-routing the remaining
stomach “pouch” into the small intestine. It is reported
that such surgery can affect the composition of the
gut microbiota; subjects who have had gastric bypass
have a different microbiota composition from that of
lean or obese subjects, with increased contents of both
Gammaproteobacteria (including Enterobacteriaceae),
and Fusobacteriaceae, and with proportional decreases in
Clostridiathus content [14]. These authors also suggested
that changes in the duration of gut wall exposure to
food, and the different pH distribution along the gut after
bypass surgery, might contribute to changes in the gut
microbiota [14].
Overall, the aims of this review are, ﬁrst, to review
current evidence on the association of obesity [and obesity-
related complications] with the composition of the gut
microbiota, and second, to review how various treatments
of obesity (e.g., diet and bariatric surgery) might modulate
the composition of the gut microbiota, so that it may con-
tribute to the reduction of the risk of obesity and of its
complications.
Obesity and the gut microbiota
The microbiota of people with obesity contains lower
proportions of Bacteroidetes and higher proportions of
Firmicutes than those from people without obesity [15], as
is also seen in pregnancy. Bacteroidetes and S. aureus
concentrations were also signiﬁcantly higher in overweight
than in normal weight women and higher proportions of
Bacteroidetes were associated with excessive weight
gain during pregnancy [16]. Obesity-related differences
have also been identiﬁed in the contents of microbes, such
as Clostridium innocuum, Eubacterium dolichum, Cateni-
bacterium mitsuokai, Lactobacillus reuteri, Lactobacillus
sakei, and Actinobacteria, and in numbers of rarer Archaea
organisms such as Methanobrevibacter smithii [15, 17, 18].
This clinical evidence suggests that there is a tight
association between the gut microbiota and body weight
regulation, as is already reported in animal studies. In the
1980s, Wostman’s group observed that germ-free (GF)
mice required higher energy intakes to reach and maintain
target body mass than did wild mice [19].
These ﬁndings were clariﬁed by Bached et al. who found
a 47% larger total fat mass in wild than in GF mice, despite
GF animals having higher energy intakes. In addition, when
the gut of GF mice was colonized with cecum-derived
microbiota from wild mice, those GF mice increased their
body fat mass by 60% [3]. It has also been reported that GF
mice fed with high-carbohydrate/high-fat Western diet for
8 weeks gained less weight than non-GF mice. Furthermore,
GF mice did not experience derangements of glucose
metabolism compared with wild-type mice [20].
Looking further at the gut microbiota, Ley et al. analyzed
>5000 bacterial 16S rRNA sequences corresponding to the
cecal microbiota seen in lean and in genetically obese
animals. They found that the relative proportion of two
predominant bacterial divisions differed between the mice
homozygous for a leptin gene mutation, causing phenotypic
obesity and controls, with 50% fewer Bacteroides and 50%
more Firmicutes organisms in the microbiota of lean wild-
type animals versus those with obesity.
Turnbaugh et al. later studied microbiota colonization of
GF wild-type mice with the cecal microbiota from lean or
obese donors; animals colonized with the microbiota from
obese mice showed signiﬁcantly greater percentage increa-
ses in body fat than did mice colonized with the microbiota
from lean donors [4].
Several studies have investigated potential mechanisms
underlying the associations between obesity and the
microbiota (Fig. 1) that might account for the different
adiposity phenotypes seen with a different microbiota
composition, seeking to determine how microbiota com-
position might modulate host energy metabolism and
whether the induced changes might be transmissible [4].
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The abundance of Bacteroidetes in the gut microbiota has
been directly associated with fecal concentrations of
SCFAs, especially propionate, butyrate, and acetate fatty
acids, which interact with G-protein-coupled receptors
(GPCRs), and speciﬁcally with the GPR41 (free fatty acid
receptor 3, or FFAR3) expressed in the gut, adipocytes, and
the peripheral nervous system. This receptor binds primarily
to Gi/Go proteins, while GPR43 (free fatty acid receptor 2,
or FFAR2) mainly activates Gi/Go proteins in the gut and
adipose tissue. Further data suggest that SCFA binding to
GPR43 may modulate the immune response by speciﬁcally
reducing the release of inﬂammatory cytokines [21], and by
increasing hypothalamic sensitivity to leptin [22, 23].
Studies in Gpr41-deﬁcient mice suggest that activation of
GPR41 by SCFA stimulates the release of PYY, which
induces satiety and reduces food intake; when expressed in
the adipose tissue, GPR41 stimulates leptin secretion, add-
ing to the induction of satiety [23].
In adipose tissue, GPR43-pathway activation suppresses
insulin signaling, thereby inhibiting fat accumulation and
stimulating lipolysis in adipocytes. Gut GPR43 promotes
the secretion of glucagon-like peptide 1 (GLP-1), which in
turn increases postprandial insulin release and decreases
glucagon secretion [24, 25]. Supporting these observations,
Gpr43-deﬁcient mice fed with high-carbohydrate, high-fat
diets develop lower body mass and higher lean mass than
their wild-type siblings [26]. However, in comparison with
those with normal weight, people with obesity have a
greater abundance of bacteria capable of fermenting car-
bohydrates [and thus increasing the rate of SCFA bio-
synthesis], providing an extra energy substrate to the host,
which is then stored as lipids or glucose. Besides these
mechanisms, the changes in the composition of the gut
microbiota seen in obesity decrease the expression of
fasting-induced adipose factor (FIAF); since this is a cir-
culating lipoprotein lipase inhibitor (LPL), this leads to
increased white fat storage [3].
Changes in microbiota composition to a predominance of
Gram-negative bacterial species may also alter the protein
structure in gut endothelial “tight junctions”, leading to
increased intestinal permeability, increasing the absorption of
bacterial endotoxins such as lipopolysaccharides (LPS) into
the circulation through CD14 receptor binding, which
induces increased LPS-signaling cascades that lead to the
production of pro-inﬂammatory cytokines, as seen with the
development of obesity and increased insulin resistance [27].
Changes in the microbiota also activate the gut endo-
cannabinoid system through stimulation of endothelial CB1
receptors, which contribute to increases in gut permeability,
further increasing plasma LPS levels with increased gut
barrier disruption and increased endocannabinoid system
activity in both the gut and in adipose tissue, aggravating
the initial disorders and leading to a vicious cycle [28].
The gut microbiota and obesity-related
comorbidities
Type 2 diabetes
It is widely recognized that the gut microbiota is further
modiﬁed in obesity-related comorbidities, such as type 2
diabetes (T2D) [27, 28]. Larsen et al. have shown that
Firmicutes concentrations in the microbiota of adults with
type 2 diabetes (T2D) are signiﬁcantly increased versus
those from comparable adults without diabetes [29]. Inter-
estingly, those authors showed that plasma glucose (but not
body mass index [BMI]) was positively correlated with the
Bacteroidetes to Firmicutes ratio.
Faecalibacterium prausnitzii, from the phylum
Firmicutes, is one of the most abundant organisms in the
human gut microbiota, but is reduced in people with T2D in
association with the increases in circulating levels of
inﬂammatory markers [30]. Xiuyng Z et al. examined the
relationship of the gut microbiota with the appearance of
T2D in 121 individuals with normal glucose tolerance
[NGT], prediabetes, or a newly diagnosed T2D, and
found that butyrate-producing bacteria (e.g., Akkermansia
muciniphila and Faecalibacterium prausnitzii) were most
abundant in those with NGT, but that Bacteroides organism
contents were halved in those with T2D versus those with
Fig. 1 Mechanisms underlying the association between obesity.
Obesity is associated with a high abundance of bacteria capable of
fermenting carbohydrates that increases the rate of short-chain fatty
acid (SCFA) biosynthesis, providing an extra source of energy for the
host, which ends up being stored as lipids or glucose. The decreased
expression of fasting-induced adipose factor (FIAF), a circulating
lipoprotein lipase inhibitor (LPL), results in an increased fat storage in
the white adipose tissue. Latter changes in the microbiota activate the
endocannabinoid system in the gut. This mechanism contributes to
increase gut permeability, which enhances plasma LPS levels and
exacerbates gut barrier disruption. The increased endocannabinoid
tone along with the increased LPS levels contribute to the increase of
adipogenesis
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either NGT or prediabetes [31]. Overweight and obesity
are becoming more prevalent among people with type 1
diabetes (T1D) [32], and some recent data suggest a rela-
tionship between T1D and the gut microbiota, with
microbial-regulated metabolites being modiﬁed in children
before the development of either T1DM or of the relevant
autoantibodies [33], in a population showing changes in the
gut microbiota with disease progression [34] and showing
less diversity with progression of the disease than in
those without T1D, suggesting that some gut organisms
(Bacteroides ovatus and Bacteroides fragilis) may exert
some protection against progression to T1D [34]. The same
pattern has been observed in T2D progression, being
accompanied with increases in Bacteroidetes and decreases
in Firmicutes in the microbiota, as compared with non-
diabetics [29]. In particular, the gut microbiota in NOD
mice deﬁcient in MyD88 seems to be protective against
T1D development, a protective effect blunted by oral anti-
biotic treatment [35]. The role of the gut microbiota in the
development of autoimmunity and of T1D warrants further
investigation.
Metabolic syndrome
Obesity, T2D, and metabolic syndrome are conditions
sharing a range of phenotypes and with substantial numbers
of interactions between genetic/epigenetic risk factors and
environmental inﬂuences, recently including the gut
microbiota. Pseudo-germ-free rodents have been used to
evaluate causative links between the gut microbiota and
obesity [36, 37]. Further work using toll-like receptor 5
(TLR5)-knockout mice and leptin-deﬁcient(ob/ob) mice
that develop hyperphagia-induced obesity and insulin
resistance [38, 39] showed that eliminating the bulk of the
gut microbiota by ampicillin–neomycin treatment induced
reductions in inﬂammation and insulin resistance [36, 37],
suggesting that the gut microbiota may contribute to the
development of a metabolic syndrome. Such potentially
causative relationships have also been investigated in a
recent clinical trial of “transplantation” of the gut micro-
biota [40]; obese participants received fecal transplants from
lean donors or, in controls of their own fecal microbiotas,
showed that lean-microbiota receivers became more insulin-
sensitive over 6 weeks, showing for the ﬁrst time a causa-
tive role for the healthy gut microbiota in the control of
abnormal insulin resistance in humans, providing also the
ﬁrst evidence of the gut microbiota as a “pathogen-like”
factor satisfying Koch’s postulates as a causative agent for a
speciﬁc condition. In addition, Ussar et al., using three
inbred strains of mice exposed to long-term environmental
intervention and short-term dietary challenge, showed
that in mice with a permissive genetic background, mod-
ulation of the microbiota could reduce metabolic syndrome
disorders; these data also suggest that there is an association
between speciﬁc microbiontal bacterial composition and
different metabolic phenotypes, suggesting complex inter-
actions between the gut microbiota, host genetics, and
environmental risk factors (diet/medication/lifestyle) [41].
Cardiovascular diseases
It is widely recognized that there is a close relationship
between inﬂammatory and metabolic pathways in the
etiology of atherosclerosis, as well as for the development
of obesity and metabolic syndrome [42]. Gut microbiontal
abnormalities may affect lipid metabolism and ather-
omatous plaque development through several inﬂammatory-
dependent mechanisms. LPS, the major component of the
outer membrane of Gram-negative bacteria [43], passes
through the gut wall by two main mechanisms, “passive”
chylomicron-associated transport, and leakage through
faulty tight junctions (leaky gut). LPS, which acts through
Toll-like receptors (TLRs) has been linked with insulin
resistance and increased macrophage inﬁltration of adipose
tissue. Since the gut microbiota is the main source of LPS in
humans, it could inﬂuence host metabolic syndrome and
cardiovascular risk through upregulation of inﬂammatory
signaling pathways [44, 45].
TLR signaling-deﬁcient mice are characterized by
reduced adiposity and improved glycemia [37, 46–48], and
ablation of the speciﬁc TLR5 gene in mice leads to
hyperphagia and metabolic syndrome abnormalities [37].
Consistent differences in gut microbiota composition
are seen with these phenotypes, and importantly, these
phenotypes are transmissible through the transplantation
of microbiota from TLR5-deﬁcient to germ-free mice,
with the development of obesity and increased insulin
resistance [37]. These observations support the suggested
connection between the immune system modulation
and host metabolism through modiﬁcations of the gut
microbiota.
More recent experimental and clinical studies have
shown that the contribution of the gut microbiota to
increased cardiovascular disease (CVD) risks involves
compound molecules, which are synthesized by the intest-
inal microbiota [49]; such compounds also increase the risk
of arterial thrombosis [50, 51] and worsen ischemic stroke
outcomes [52]. Diet composition (particularly high-fat
diets) seems to be a major factor inﬂuencing the effect of
the gut microbiota on CVD risks [53], though gut micro-
biota dysbiosis can also contribute to the development
of hypertension in mice [54] and humans [55]; speciﬁcally,
high-ﬁber diets, which increased murine gut microbiota
short-chain fatty acid (SCFA) production, reduced
systolic and diastolic blood pressures in mouse models of
hypertension [56], while SCFA acetate supplementation
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downregulated the renin–angiotensin system in overweight/
obese pregnant women [57].
CVD has been associated in a dose-dependent manner
with circulating levels of betaine, choline, and trimethyla-
mine N-oxide (TMAO) in humans [58], and the gut
microbiota produce trimethylamine (TMA), a bacterial
choline metabolite formed after consumption of dietary
phosphatidylcholine choline and L-carnitine; this TMA is
absorbed into the portal circulation and converted in the
liver into trimethylamine N-oxide (TMAO) [49, 58]. Koeth
et al. found that high-plasma TMAO concentrations were
signiﬁcantly associated with incident CV events and with
fasting plasma carnitine concentrations [49]; in addition,
they showed that L-carnitine-supplemented ApoE−/− mice
developed approximately double the aortic root athero-
sclerotic plaque seen in chow-fed control mice [49]. How-
ever, these effects were abolished by elimination of the
commensal gut microbiota in the L-carnitine-supplemented
ApoE−/− mice, also through a decrease of TMA and TMAO
levels. The choline supplementation avoided foam cell
inﬁltration in the plaque and contributed to decrease the
plaque size in ApoE−/− mice [49].
Clinical studies have reported that TMAO levels are an
independent predictor of mortality risk in coronary artery
disease [59, 60], but this has not been conﬁrmed in other
studies [61]. Further studies are, therefore, required to
determine whether microbiota-derived TMAO does induce
atherosclerosis, especially in the context of overweight and
obesity.
Nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is associated
with obesity and characterized by excessive fat inﬁltration
in the liver, categorized histologically as either nonalcoholic
fatty liver (NAFL) or as having progressed to nonalcoholic
steatohepatitis (NASH) in about 25% of cases [62]. Thus,
liver fat accumulation alone may not account for disease
progression, and other factors may promote progression to
NASH. The gut microbiota may be a contributory factor for
several reasons, ﬁrst, it is involved in carbohydrates, amino
acids, and fatty acid metabolism, thereby inﬂuencing
nutrient supplies [63]; second, it is involved in the mod-
ulation and development of host immunity [64], and spe-
ciﬁc types of microbiota can affect the development/
progress of inﬂammation in the liver as in adipose tissue
and the vasculature [as discussed above]. The microbiota
transplantation from TLR5 knockout mice to wild-type
germ-free mice resulted in weight gain, chronic inﬂamma-
tion, and glucose derangements, thus allowing to hypothe-
size an association between host immune activity and the
gut microbiota [37]. In addition, the gut microbiota may
modulate gut hormone secretion (e.g., glucagon-like peptide
1 (GLP-1)) [65]. For example, Dumas et al. showed that
microbial modulation of phosphatidylcholine (PC) meta-
bolism increased inﬂuential steatosis in mice susceptible to
insulin resistance and NASH through their ampliﬁed
microbial destruction of PC to form methylamines (as
measured in the urine), since PC is necessary for VLDL
synthesis. As impaired PC secretion leads to increased
hepatic triglyceride deposition, those ﬁndings suggest a
mechanistic link between the gut microbiota and progres-
sion from NAFL to NASH [66]. Observations in humans
provide a possible link between choline-deﬁcient diet-
induced fatty liver and the gut microbiota, since on that diet,
alterations of the gut microbiome paralleled fatty liver
development, suggesting associations between diet, the gut
microbiome, and liver health [67]. Increased risks of pro-
gression to NASH may also be associated with the gut
microbiota through their secretion of ethanol, well known to
have adverse effects on liver health, since alcohol-free food
consumption induces increases in blood alcohol content,
and the gut microbiota is a major source of endogenous
alcohol production [68, 69]. Studies showing that mice with
the abnormal gut microbiota had elevated breath alcohol
levels that were reduced by oral neomycin treatment [70]
support this hypothesis; these authors conclude that since
individuals with NASH are usually obese and since the
histology of NASH matches that of alcoholic liver disease,
they may produce more endogenous alcohol than those
without disease progression [70]. This hypothesis is sup-
ported by the ﬁnding that patients with NASH have higher
blood ethanol concentrations than those with NAFLD
(mean 0.12 µmol/µl vs. 0.09 µmol/µl, respectively) [71].
Interestingly, Zhu et al. in an alcohol-free population of
children and adolescents conﬁrmed a measureable blood
ethanol concentration in obese subjects with, but not in
those without, NASH, that was also associated with a sig-
niﬁcantly higher microbiome content of Escherichia genus
bacteria in NASH+ subjects. Since Escherichia bacteria are
known ethanol producers, these ﬁndings support the
hypothesis that these microbiontal organisms could con-
tribute to NAFDL progression to NASH and for the asso-
ciation of NASH with elevated blood ethanol levels [72].
Weight loss and the gut microbiota
Diet
The microbiota contains principally organisms from the
Bacteroides and Firmicutes phyla. The Bacteriodes have a
high capacity for digesting dietary polysaccharides, and
those species are more abundant in lean people than in
morbid obesity, where dysbiotic intestinal microbiota are
common with increased Firmicutes phyla content versus
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that seen in lean subjects. Recent research has also docu-
mented that the dysbiosis seen in obesity could be changed
by several months on a low-energy diet. Thus, different
compositions of the gut microbiota are associated with
differences in the degradation of various otherwise indi-
gestible polysaccharides, which could contribute to the risks
of developing obesity [73]. It has also been reported that the
intake of some micronutrients, fatty acids, prebiotics, and
probiotics could have an impact on gut microbiota com-
position and on the regulation of gene expression at the
liver, muscle, and adipose tissue site [74].
Overall, the production and the activation of B and K
vitamins are induced by the fermentation of short-chain fatty
acids coming from carbohydrates, ammonia, and nitrogenous
compounds by the gut microbiota. This results in an
increased intake of energy from the food at gut level. The
high intake of carbohydrates had an impact on gut micro-
biota composition, promoting the reduction of pH in the gut
lumen that in turn modiﬁes bacterial metabolism [75].
It has been reported that Firmicutes had an inhibitory
effect on lipoprotein lipase (LPL) inhibitor release, thus
resulting in an increased enzymatic activity and a tendency
to enhance surplus energy accumulation as fat [76].
Furthermore, since obesity results from abnormal regulation
of energy intake, expenditure and conservation and micro-
biontal microorganisms contribute to the regulation of
energy accumulation from the diet; both abnormal micro-
biontal composition and activity and excessive dietary
intake must contribute to adiposity through increasing the
accumulation of body fat [75].
However, other studies have not conﬁrmed ﬁndings on
the contribution of various bacterial microbiota components
to the development of obesity; in particular, the Bacter-
oides/Firmicutes ratio has not always been found to be a
signiﬁcant modulatory factor for obesity [77]. These dis-
crepancies imply that further undetected variants in the gut
microbiota may also contribute to obesity risks, or that
unconsidered factors, dietary, genetic, or environmental are
affecting microbiota function. Dietary carbohydrates,
including structural polysaccharides, plant-based oligo-
saccharides, and starches resistant to digestion in the small
intestine, are fermented by the large intestine microbiota,
providing the main source of energy supporting microbial
growth in the colon.
Fermentation releases energy as short-chain fatty acids
(SCFAs), which is a energy source for host cells [78]. In
turn, the decreased assumption of fermentable carbohy-
drates could have an effect on the composition of large gut
bacterial phyla. The effect of a nutritional pattern char-
acterized by a decreased carbohydrate intake on gut bac-
terial components of obese subjects has been investigated
by Duncan et al., reporting that carbohydrate intake
decreased, so that the total fecal SCFA was reduced.
Furthermore, the decreased carbohydrate intake resulted in a
decrease in the Roseburia spp., the Eubacterium rectale
subgroups of cluster XIVa and biﬁdobacteria [78].
Since weight loss on diets rich in protein but low in
fermentable carbohydrates alter colonic bacterial popula-
tions, with further implications for intestinal health and
function, variations in the colonic microbiota might be one
such factor [78], further studies in this area are clearly
necessary.
In support of observations discussed in obesity, recent
studies have shown that anorexia is characterized by an
imbalance in Gram+/Gram− abundance in the gut micro-
biota with an increased abundance of Bacteroidetes and a
reduced abundance of Firmicutes, which is the inverse of
the ﬁndings seen in obesity. Furthermore, since the
relative abundance of Firmicutes [including Ruminococcus,
Roseburia, and Clostridium fermenting carbohydrates] is
reduced in people with anorexia, the fecal butyrate con-
centration is lower in obesity than in anorexia [79], though
it remains to be established whether this ﬁnding in anorexia
is caused by dietary restriction or whether it has any speciﬁc
causative role for weight loss.
To evaluate the temporal relationships between food
intake, intestinal microbiota, and metabolic and inﬂamma-
tory phenotypes, Cotillard et al. studied weight loss and
weight stabilization following dietary restriction in people
with obesity or overweight. They found that individuals
with reduced microbial gene richness (by 40%) showed
marked low-grade inﬂammation and showed increased
metabolic syndrome abnormalities. Weight loss improved
gene richness and clinical phenotype, but was less effective
in reducing markers of inﬂammation in people with initially
lower microbial gene richness, while low genetic richness
seemed to have predictive potential for the effectiveness of
dietary intervention [80].
Probiotics could have an important role in this regard,
because resoring the tight junctions at gut level avoid the
translocation of lipopolysaccharide in the bloodstream. This
could contribute to prevent the onset of a chronic inﬂam-
matory milieu that it is well known to contribute to insulin
resistance [81].
To investigate the modulatory effect of oolong tea poly-
phenols (OTP) on intestinal microbiota, the inﬂuence of OTP
[prepared by column chromatography, on the composition of
the intestinal ﬂora has been evaluated by high-throughput
gene sequencing in a mouse model of obesity induced by
high-fat diet (HFD); large increases in gut bacterial biodi-
versity and in the abundance of butyrate and acetate-
producing bacteria were found, with signiﬁcant increases in
Bacteroidetes and decreases in Firmicutes in the microbiota
after 4 weeks administration of OTP [82]. The corresponding
decrease in the Firmicutes/Bacteroidetes ratio reﬂected
a positive modulating effect of OTP on the intestinal
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microbiota, and since OTP is rich in tea catechins, especially
O-methylated derivatives, it may also have probiotic activity
and be useful as a functional food component contributing to
the prevention of obesity-related metabolic disorders through
modiﬁcation of the intestinal microbiota [82].
Few reported studies have examined the relationship
between gut ﬂora and bacterial metabolite production. One
recent study found that galactooligosaccharide (GOS) pro-
biotics that beneﬁcially affect host intestinal microbiota and
gut metabolite production, decreased the abundance of
Ruminococcaceae and Oscillibacter in the mouse micro-
biota and decreased the production of ~31 metabolites,
including oleic acid, arachidic acid, and behenic acid in the
intestine as well as decreasing blood triglyceride content
versus controls, suggesting that GOS could improve murine
lipid metabolism. Also, on diets rich in GOS, mouse the
abundance of Alloprevotella, Bacteroides, and Parasutterell
in the microbiota were increased [83]. While control blood
glucose concentrations were signiﬁcantly higher than those
of the GOS-fed animals, the gut contents of Coprococcus
and Odoribacter, [butyrate-producing bacteria] were lower
and butyrate, which reduces plasma glucose content, was
signiﬁcantly downregulated with potentially detrimental
effects on host glycemia, as mentioned. However, this effect
could optimize the effects of consumption of combinations
of probiotics, some of which increase gluconeogenesis [83],
methods of prebiotic integration and the development of
preventive prebiotic interventions [83].
Bariatric surgery
Bariatric surgery is an increasingly popular therapeutic
option for treating people with morbid obesity and achieves
the largest BMI reductions [84]. Weight loss after bariatric
surgery is associated with microbiota modiﬁcations as are
seen with any surgical procedure [85]. Recent research on
the effects of different bariatric surgical procedures, in
particular Roux-en-Y gastric bypass (RYGB) suggests it
increases Proteobacteria and decreases Firmicutes micro-
biota content; sleeve gastrectomy (LSG) leading to less
marked gut microbiota alterations with increased anti-
inﬂammatory Fecali bacterium prausnitzii abundance
though alterations in microbiota Fecalibacterium species
abundance seen after RYGB have been inconsistent [85].
Some work showing increased and decreased abundance of
Gamma proteobacteria and Clostridia, respectively in the
feces of obese subjects after bariatric surgery [86]. Other
work has shown increased abundance of Bacteroides/Pre-
votella and Escherichia coli [a member of the Gamma-
proteobacteria class] after bariatric surgery, supporting
earlier ﬁndings [32]. Liou et al. also demonstrated that
alterations of the intestinal microbiota after Roux-en-Y
gastric bypass (RYGB) were associated with postoperative
reductions in both host body weight and percentage fat
mass [87]. Furthermore, the transfer of the post-RYGB
intestinal microbiota to germ-free mice induced weight loss,
a ﬁnding in accordance with the recent ﬁnding that an obese
phenotype could be induced in germ-free mice through the
introduction of the obese subject gut microbiota [87].
Comparison of the impact of RYGB versus SG on post
procedure intestinal microbiota in Sprague-Dawley rats
(SD), showed that RYGB, but not SG, altered the intestinal
microbiota, reducing the variety of microbiota organisms in
the intestine, while Gammaproteobacteria abundance was
negatively correlated with achieved body weight post sur-
gery, so that an altered microbiota has the potential to be a
factor contributing to the achievement of stable reductions
in postoperative weight [88].
Conclusions
Overall, currently available evidence suggests that changes
in the gut microbiota could contribute to the pathogenesis of
obesity and to the development of obesity-related metabolic
disorders, including type 2 diabetes, NAFLD, metabolic
syndrome, and cardiovascular disease.
Obesity treatments such as calorie reduced diets and/or
bariatric surgery modify the gut microbiota in ways that are
associated with health beneﬁts, supporting the hypothesis
that changing gut microbiontal composition has the poten-
tial to provide an additional mechanism for achieving stable
weight loss.
However, further studies are needed to better understand
the mechanisms of the observed associations between gut
microbiota and obesity, the role of the colonic microbiota,
and to determine whether manipulation of the gut microbiota
through diet, with or without increased intakes of pre/pro-
biotics, could provide potential therapeutic options con-
tributing to the prevention or treatment of human obesity.
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